Repligen SecreFlo sNDA approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Repligen gains approval Nov. 1 to expand indications for SecreFlo (secretin) to include stimulation of pancreatic secretions to facilitate identification and cannulation of pancreatic ducts in patients undergoing endoscopic retrograde cholangio-pancreatography (ERCP). A randomized, placebo controlled crossover study in 31 patients undergoing ERCP resulted in 25 of 28 successful cannulations of the minor duct for SecreFlo compared to 1 of 16 for placebo, labeling notes. SecreFlo previously was approved for stimulation of pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction and for stimulation of gastrin secretion to aid in the diagnosis of gastrinom
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.